CN1726987A - Combined of Chinese traditional medicine for lowering blood sugar, preparation and discrimination method - Google Patents
Combined of Chinese traditional medicine for lowering blood sugar, preparation and discrimination method Download PDFInfo
- Publication number
- CN1726987A CN1726987A CN 200410070623 CN200410070623A CN1726987A CN 1726987 A CN1726987 A CN 1726987A CN 200410070623 CN200410070623 CN 200410070623 CN 200410070623 A CN200410070623 A CN 200410070623A CN 1726987 A CN1726987 A CN 1726987A
- Authority
- CN
- China
- Prior art keywords
- solution
- chinese medicine
- radix ginseng
- rhizoma
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims description 13
- 238000012850 discrimination method Methods 0.000 title claims description 6
- 210000004369 blood Anatomy 0.000 title description 77
- 239000008280 blood Substances 0.000 title description 77
- 235000000346 sugar Nutrition 0.000 title description 25
- 238000000034 method Methods 0.000 claims abstract description 21
- 230000008569 process Effects 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 49
- 238000012360 testing method Methods 0.000 claims description 26
- 241000208340 Araliaceae Species 0.000 claims description 25
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 25
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 25
- 235000008434 ginseng Nutrition 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 239000013558 reference substance Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 238000004809 thin layer chromatography Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 229960004756 ethanol Drugs 0.000 claims description 8
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims description 4
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 241000605447 Anemarrhena Species 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 claims description 2
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 claims description 2
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 2
- 230000005284 excitation Effects 0.000 claims description 2
- 230000003760 hair shine Effects 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- WCYAALZQFZMMOM-UHFFFAOYSA-N methanol;sulfuric acid Chemical compound OC.OS(O)(=O)=O WCYAALZQFZMMOM-UHFFFAOYSA-N 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001553 phloroglucinol Drugs 0.000 claims description 2
- 238000000079 presaturation Methods 0.000 claims description 2
- 229960003371 protocatechualdehyde Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 235000019640 taste Nutrition 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical class CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 claims 1
- HYGYSIDIKIGPJA-UHFFFAOYSA-N chloroform;ethyl acetate;methanol Chemical compound OC.ClC(Cl)Cl.CCOC(C)=O HYGYSIDIKIGPJA-UHFFFAOYSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 54
- 239000008103 glucose Substances 0.000 description 54
- 230000000694 effects Effects 0.000 description 47
- 206010012601 diabetes mellitus Diseases 0.000 description 43
- 208000024891 symptom Diseases 0.000 description 30
- 230000007812 deficiency Effects 0.000 description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 18
- 210000002700 urine Anatomy 0.000 description 18
- 208000011580 syndromic disease Diseases 0.000 description 15
- 235000012054 meals Nutrition 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 230000035922 thirst Effects 0.000 description 13
- 230000008859 change Effects 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 238000010791 quenching Methods 0.000 description 10
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 9
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 230000000171 quenching effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000003414 extremity Anatomy 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000001603 reducing effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 206010016256 fatigue Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 206010036067 polydipsia Diseases 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 5
- 206010013954 Dysphoria Diseases 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 229920002527 Glycogen Polymers 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229960005139 epinephrine Drugs 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 229940096919 glycogen Drugs 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- 235000019615 sensations Nutrition 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 206010012655 Diabetic complications Diseases 0.000 description 4
- 206010014080 Ecchymosis Diseases 0.000 description 4
- 208000007976 Ketosis Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000004140 ketosis Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- BUCXEFZXWKUCCY-UHFFFAOYSA-N 4-methyl-3-(2-phenylethyl)-1,2,4-oxadiazol-5-one Chemical compound O1C(=O)N(C)C(CCC=2C=CC=CC=2)=N1 BUCXEFZXWKUCCY-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010012669 Diabetic hyperosmolar coma Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- XECUMCLPUKPRLJ-UHFFFAOYSA-N [O].C1=CN=CN=C1 Chemical compound [O].C1=CN=CN=C1 XECUMCLPUKPRLJ-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- KKIGLNUFXVPUAV-UHFFFAOYSA-N azane chloroform ethyl acetate methanol Chemical compound N.CO.C(C)(=O)OCC.C(Cl)(Cl)Cl KKIGLNUFXVPUAV-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- XRIVRYRXJYCJTQ-UHFFFAOYSA-N benzene;ethyl acetate;formic acid Chemical compound OC=O.CCOC(C)=O.C1=CC=CC=C1 XRIVRYRXJYCJTQ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000026686 chromosomal inheritance Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000002229 photoelectron microspectroscopy Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- -1 tabletting Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A glycemic Chinese medicine is prepared from 8 Chinese-medicinal materials including rehmannia root, coptis root, wolfberry fruit, red sage root, etc and the pharmacologically acceptable excipient. Its preparing process, its varifying method and its content measuring method are also disclosed.
Description
Invention field
The present invention relates to a kind of Chinese medicine composition of treatment, the present invention also relates to preparation method and the discrimination method and the content assaying method of this Chinese medicine composition.
Background technology
Chinese medicine thinks that the basic pathogenesis of diabetes (diabetes) is that the deficiency of YIN is scorching, and the deficiency of YIN is this, and scorching for marking, the two reciprocal causation increases the weight of mutually.Gas is cloudy smart the change, and the deficiency of YIN then changing of gas mistake is given birth to the basis, and with the passing of time the scorching impairment of QI the moon that can consume again can cause deficiency of both QI and YIN; The handsome blood of the deficiency of vital energy is unable, and the deficiency of YIN is blood viscous then, causes hematogenous blockage and forms blood stasis.So intense heat due to deficiency of YIN, blood stasis due to qi deficiency is the main pathological change of diabetes.Medicine of the present invention promptly at this pathogenesis development, has nourishing YIN and clearing away heat, the pure Chinese medicinal preparation of the effect of benefiting QI for activating blood circulation.Test confirms that the diabetes (type ii diabetes) that its verification belongs to the scorching double Qi deficiency blood stasis type of the deficiency of YIN has curative effect preferably, thereby has finished the present invention.
Goal of the invention
The purpose of this invention is to provide the littler Chinese medicine composition of a kind of blood sugar lowering better efficacy side effect.
Another object of the present invention provides the preparation method of this Chinese medicine composition.
Another purpose of the present invention provides the discrimination method of this Chinese medicine composition.
A further object of the present invention provides the content assaying method of this Chinese medicine composition.
Summary of the invention
Medicine of the present invention is made up of effective ingredient and/or pharmaceutically acceptable excipient, wherein prepares described raw materials of effective components and comprises following parts by weight of Chinese traditional medicine material:
Radix Rehmanniae 4-8 Rhizoma Anemarrhenae 3-7
Rhizoma Coptidis 1-4 Cortex Lycii 2-6
Fructus Lycii 1-4 Rhizoma Polygonati Odorati 2-5
Radix Ginseng 1-4 Radix Salviae Miltiorrhizae 2-5.
In order to obtain better therapeutic, the consumption of preferred Chinese crude drug raw material is:
Radix Rehmanniae 5-7 Rhizoma Anemarrhenae 4-6
Rhizoma Coptidis 1-3 Cortex Lycii 3-5
Fructus Lycii 1-3 Rhizoma Polygonati Odorati 2-4
Radix Ginseng 1-3 Radix Salviae Miltiorrhizae 2-4.
In order to obtain optimum curative effect, more preferably the consumption of raw material of Chinese medicine is:
Radix Rehmanniae 6 Rhizoma Anemarrhenaes 5
Rhizoma Coptidis 2 Cortex Lycii 4
Fructus Lycii 2 Rhizoma Polygonati Odorati 3
Radix Ginseng 2 Radix Salviae Miltiorrhizaes 3.
Wherein used Radix Ginseng can use Radix Ginseng, Radix Ginseng Rubra or its extract to replace.
The method for preparing medicine of the present invention can take by weighing above-mentioned consumption, and directly with the dry levigation of raw material of Chinese medicine difference, mixing is made powder.Also above-mentioned raw material of Chinese medicine can be extracted and refining carry or the 60-80% ethanol extraction, reclaim or concentrated, make various dosage forms such as capsule, tablet, granule, oral liquid etc. with pharmaceutically acceptable excipient as water.
The preparation method of medicine of the present invention is preferably Radix Ginseng and partly measures Rhizoma Anemarrhenae powder and is broken into fine powder, sieves; Rhizoma Coptidis powder is broken into coarse powder, adds an amount of decoction of water 3 times, and each 1.5 hours, gradation filtered, merging filtrate; The Rhizoma Anemarrhenae extracting in water of all the other five tastes and half amount three times, each 1.5 hours, merging filtrate merged filtrate and Rhizoma Coptidis filtrate, and being concentrated into relative density is the thick paste of 1.18 (60 ℃); Add Radix Ginseng and partly measure Rhizoma Anemarrhenae fine powder, mixing, drying is ground into fine powder, and adding starch is an amount of, and mixing sieves, and packing is made 1000, promptly.
Medicine of the present invention has the effect of replenishing YIN and removing heat, benefiting QI for activating blood circulation, is used for the treatment of the diabetes (type ii diabetes) of the scorching double Qi deficiency blood stasis type of the deficiency of YIN.Clinical test results shows: medicine of the present invention can improve type ii diabetes patient's clinical symptoms significantly, reduce fasting glucose, 2 hours after the meal blood glucose, twenty-four-hour urine sugar quantitatively and glycosylated hemoglobin, and can regulate disorders of lipid metabolism, improving hemorheology, is effective Chinese patent medicine of treatment diabetes (type ii diabetes).Do not see untoward reaction in the treatment.
In acute toxicity test, in 24 hours, press Cmax and maximum tolerance volume is given mouse stomach with medicine of the present invention, the no any toxicity and phenomena of mortality generation in seven days, proving quenches one's thirst pacifies LD to mice
50＞20.0g/kg, this dosage are 444 times of clinical people's consumption.Drug oral of the present invention.One time 3,3 times on the one.In long term toxicity test,, divide three dosage groups (be equivalent to respectively clinical human 50,100,150 times) and matched group, administration 90 days to the rat oral gavage peace of quenching one's thirst.Respectively at weighing in 15,30,45,60,75,90 days before the administration and after the administration, again respectively at before the administration, administration mid-term and finish three times of administration and get rat blood serum and survey its hemogram, SGPT, BUN, and after finishing administration, get blood and survey its blood sugar content, get urine and survey its routine urinalysis, and the heart, liver, lung, kidney, stomach, adrenal gland, pancreas, the testis (or uterus) of winning rat are respectively done the pathomorphology inspection.Experimental result shows, takes each dosage peace of quenching one's thirst for a long time for rat, with the matched group comparison, rat body weight do not had obvious influence, and hemogram, SGPT, BUN, the routine urinalysis of rat all had no adverse effects.6.75g/kg, 4.50g/kg two dosage group rat blood sugars have the trend of reduction, be to produce due to the blood sugar reducing function owing to taking heavy dose of medicine for a long time.The rat heart, liver, spleen, lung, kidney, stomach, adrenal gland, pancreas, testis or uterus, each internal organs of brain are not all caused bad pathological changes.
In pharmacodynamic experiment research, carried out medicine of the present invention respectively: 1. normal rat and epinephrine are caused the influence of hyperglycemic rat blood sugar content; 2. epinephrine is caused the influence of mouse's blood sugar content; 3. blood oxygen pyrimidine is caused the influence of mice high blood glucose concentrations; 4. to the influence of fibrinogen content in insulin content, total cholesterol level, the blood plasma in the alloxan diabetes mice serum; 5. the experiment such as influence to removing Sc epinephrine rat blood sugar behind the pancreas, glycogen and hepatic glycogen content.Experimental result shows that quenching one's thirst to be positioned on the kinds of experiments hyperglycemia model truly has blood sugar reducing function.Normal rat blood sugar there is not obvious influence, can reduce rat and mice high blood glucose concentrations that epinephrine causes, can obviously reduce the blood sugar content of alloxan diabetes mice, and blood sugar reducing function rapidly and lastingly, can increase the content of diabetic mice serum insulin, rat to the depancreatize postoperative, the peace of quenching one's thirst still causes that to the adrenal gland increase of blood glucose and glycogen content has the obvious suppression effect, and can increase the effect that epinephrine reduces hepatic glycogen, this results suggest the peace of quenching one's thirst be not only by stimulating this mechanism of beta Cell of islet excreting insulin to produce blood sugar reducing function, but also can syntheticly make gluconeogenesis function of liver reduce the generation that reduces glucose to produce blood sugar reducing function by what suppress hepatic glycogen.On mice alloxan diabetes model, quench one's thirst to be equipped with and reduce the effect of fibrinogen content in the total cholesterol level and blood plasma in the serum, this result has pointed out the peace of quenching one's thirst that diabetes complicated hyperlipidemia and blood high viscosity syndrome are also had therapeutical effect again.
Belong to the clinical efficacy and the safety thereof of the scorching double Qi deficiency blood stasis type diabetes of the deficiency of YIN (type ii diabetes) for objective evaluation Drug therapy card of the present invention, we are according to " new Chinese medicine treatment diabetes (type ii diabetes) clinical research guideline " relevant chapters and sections, related standards with reference to WHO diabetes classification in 1980 and clinical diagnosis, the single at random blind controlled trial method of Looking is formulated the clinical observation scheme before adopting, and JIUYUE to 1996 year November nineteen ninety-five, 420 illustrations are belonged to the scorching double Qi deficiency blood stasis type diabetes of the deficiency of YIN (type ii diabetes) patient carry out II clinical trial phase (wherein 300 examples are organized in treatment, matched group 120 examples).The result shows: obvious effective rate and total effective rate that medicine verification of the present invention belongs to the scorching double Qi deficiency blood stasis type diabetes of the deficiency of YIN (type ii diabetes) patient are respectively 24.67% and 87.33%.And can obviously improve patient's clinical symptoms, and significantly reduce patient's fasting glucose, 2 hours after the meal blood glucose and twenty-four-hour urine sugar quantitatively, and can regulate disorders of lipid metabolism, improve the hemorheology index, and curative effect obviously is better than the YUQUAN WAN matched group.
Now that the effect division of Drug therapy diabetes of the present invention (type ii diabetes) is as follows:
1, improve diabetes (type ii diabetes) patient's clinical symptoms: this clinical test results shows: medicine of the present invention is that the diabetes (type ii diabetes) of the scorching double Qi deficiency blood stasis type of the deficiency of YIN has the good curing effect for Chinese medical discrimination, can obviously improve symptom, total effective rate to tcm syndrome is 94%, wherein to thirsty polydipsia, polyorexia, fatigue and weakness, the curative effect of symptoms such as vexed pain, numb limbs and tense tendons, constipation all obviously is better than YUQUAN WAN (P＜0.05-0.01) in the heart.
2, this clinical test results of carbohydrate metabolism that improves the II diabetics shows: medicine of the present invention all has tangible reduction effect to II diabetics fasting glucose, 2 hours after the meal blood glucose, twenty-four-hour urine protein quantification, glycosylated hemoglobin, compare in the group before and after the treatment, the P value is all less than 0.01, the difference significance; Its to type ii diabetes patient fasting glucose, the total effective rate of 2 hours blood glucose is respectively 87.33% and 86.33% after the meal, obviously is better than 65.83% and 65% (P＜0.01) of YUQUAN WAN matched group.
More than explanation, medicine of the present invention has the stronger glycometabolic effect of type ii diabetes patient that improves than YUQUAN WAN.
3, regulate disorders of lipid metabolism:
This clinical trial shows: treatment group hypercholesterolemia 85 examples, and matched group hypercholesterolemia 31 examples all have certain improvement after treatment, and the cholesterol average of two groups of treatment front and back is relatively learned by statistics and is handled, and the P value is all less than 0.01; The effective percentage of two groups of cholesterol reducings is respectively relatively P＜0.05 of 50.59%, 29.03%, two group of curative effect, difference significance.
Treatment group hypertriglyceridemia 184 examples, matched group hypertriglyceridemia 66 examples all have reduction in various degree after the treatment, and the triglyceride average of two groups of treatment front and back is relatively learned by statistics and is handled, and is respectively P＜0.01 and P＜0.05; Two groups front and back difference compares P＜0.01, difference significance; The effective percentage of two groups of triglyceride reducings is respectively curative effect comparison P＜0.05 between 40.22%, 24.24%, two group, difference significance.
Unusual person's 76 examples of treatment group high density lipoprotein, unusual person's 35 examples of matched group high density lipoprotein, treatment back treatment group is obviously improved (P＜0.01), and matched group does not have significant change (P＞0.05).
More than explanation: medicine of the present invention has the effect of regulating disorders of lipid metabolism preferably, and curative effect obviously is better than YUQUAN WAN.
4, improve hemorheology:
Treatment group hemorheology person 62 examples, the every index in treatment back all has in various degree to be improved, whole blood is cut viscosity, whole blood than height and is cut comparison before viscosity, plasma viscosity, Fibrinogen and the treatment than low, learn by statistics and handle, P＜0.05 or P＜0.01, difference significance or highly significant meaning illustrate the have some improvement effect of hemorheology of medicine tool of the present invention.
Specific embodiment
Embodiment 1: capsular preparation
Take by weighing Radix Rehmanniae 300g Rhizoma Anemarrhenae 250g
Rhizoma Coptidis 100g Cortex Lycii 200g
Fructus Lycii 100g Rhizoma Polygonati Odorati 150g
Radix Ginseng 100g Radix Salviae Miltiorrhizae 150g;
Decoct with water twice, 3 hours for the first time, 2 hours for the second time, collecting decoction filters, and it is the clear paste of 1.10-1.15 that filtrate is concentrated into 70-80 degree survey relative density, add 2 times of amount ethanol, fully stir, leave standstill, the leaching supernatant reclaims ethanol, and concentrating under reduced pressure becomes thick paste, add above-mentioned powder, mixing, drying, be ground into fine powder, encapsulated.
Embodiment 2: the preparation of tablet
Take by weighing Radix Rehmanniae 300g Rhizoma Anemarrhenae 360g
Rhizoma Coptidis 60g Cortex Lycii 240g
Fructus Lycii 180g Rhizoma Polygonati Odorati 120g
Radix Ginseng 60g Radix Salviae Miltiorrhizae 120g;
Decoct with water twice, 3 hours for the first time, 2 hours for the second time, collecting decoction filtered, and it is the clear paste of 1.10-1.15 that filtrate is concentrated into 70-80 degree survey relative density, adds starch and granulates, and adds magnesium stearate, tabletting, coating.
Embodiment 3: the preparation of granule
Take by weighing Radix Rehmanniae 320g Rhizoma Anemarrhenae 280g
Rhizoma Coptidis 160g Cortex Lycii 240g
Fructus Lycii 80g Rhizoma Polygonati Odorati 80g
Radix Ginseng Rubra 80g Radix Salviae Miltiorrhizae 80g;
Add 70% alcohol reflux 10-20 hour, reclaim ethanol, be condensed into thick paste, add starch and granulate.
Embodiment 4: the preparation of granule
Take by weighing Radix Rehmanniae 320g Rhizoma Anemarrhenae 240g
Rhizoma Coptidis 320g Cortex Lycii 320g
Fructus Lycii 240g Rhizoma Polygonati Odorati 160g
Radix Ginseng Rubra 240g Radix Salviae Miltiorrhizae 160g;
Add 70% alcohol reflux 10-20 hour, reclaim ethanol, be condensed into thick paste, add starch and granulate.
Test example 1
One, case is selected
(1) diagnostic criteria
1, tcm diagnosis standard
Allly have that thirsty polydipsia, rapid digestion of food are easily hungry, frequent micturition and sweet, body see that gradually patient such as become thin can make a definite diagnosis.
2, Chinese medical discrimination:
The scorching double syndrome of blood stasis due to qi deficiency of the deficiency of YIN:
Main symptom: the 2. polyorexia red constipation of 3. urinating of 1. thirsty polydipsia
4. 5. red tongue with yellow fur or few tongue of dysphoria with feverish sensation in the chest palms and soles, wiry and frequent pulse or count accurately
Inferior card: 1. 2. 3. dim complexion of spontaneous perspiration of fatigue and weakness
4. vexed in the heart pain 5. numb limbs and tense tendons 6. tongue is dark or ecchymosis arranged
Possess 3 of primary symptoms (1. 2. in one, 3. 4. 5. in binomial), 2 of inferior diseases (in the inferior disease 1. 2. in one, 3. 4. 5. 6. in one) get final product.
3, Western medicine diagnose standard
Adopt WHO tentative standard (the very sugared method of venous plasma) in 1980, all to meet one of following condition person diagnosable for diabetes:
The symptom that 1. diabetes are arranged, blood glucose 〉=11.1mmol/L (200mg/dl), or fasting glucose 〉=7.8mmol/L (140mg/dl) any time.
2. the symptom of diabetes is arranged and blood glucose does not reach above-mentioned standard, carry out 75g oral glucose tolerance test (OGTT), 2 hours blood glucose 〉=11.1mmol/L (200mg/dl).
3. as the non-diabetic symptom, remove above-mentioned standard exterior palpi and add a standard in addition, be OGTT1 hour blood glucose 〉=11.1mmol/L (200mg/dl), or another time OGTT2 hour blood glucose 〉=11.1mmol/L (200mg/dl), or another time fasting glucose 〉=7.8mmol/L (140mg/dl).
Attached 1, diabetes classification (WHO1985)
1. ketosis easily takes place in insulin-dependent (IDDM, I type).The islet cells deficiency causes insulin deficit, and is common with teenager, and HLA is relevant on the chromosome of normal and specific type, easy ill toxicity insulitis or autoimmune disease (generation insular cellular antibody ICA).
2. non-insulin-depending type (NIDDM, II type) is difficult for taking place ketosis.Common to be grown up, the overweight people is in the majority.Dominance chromosomal inheritance feature is arranged among the tendency person of family.Stress the time need insulinize (ICA does not increase).
3. all the other types diabetes relevant with other situation or syndrome have pancreatic diseases, and Insulin receptor INSR is unusual, some genetic syndrome.Other diabetes relevant (MRDM) with nutritional disorder.
Attached 2, diabetes clinical stages (diabetes association of Chinese association of traditional Chinese medicine tentative standard)
(1) prediabetes (I phase)
1. body is healthy and strong or fat, honey stomach, and endurance goes down obviously.
2. do not have typical diabetic symptom, do not have clinical nervus vasculairs complication.
3. blood glucose, blood fat are higher, often do not have glucose in urine, and glucose in urine can occur during stress state.
(2) the diabetic symptom phase (II phase)
1. typical diabetic symptom is arranged, and polydipsia, polyuria or polyphagia lose weight.
2. blood glucose or glycosylated hemoglobin, glucose in urine, blood fat (cholesterol, triglyceride, one of lipoprotein increase get final product) are all high.
3. there is not clinical nervus vasculairs complication.
(3) diabetic complications early stage (III phase)
Clinical nervus vasculairs complication appears:
1. early stage neuropathy.Unusual or autonomic nervous dysfunction of MCV or vegetative nerve function inspection are unusual.
2. microangiopathies.Simple retinopathy, the little albumin excretion rate＞30mg/24h of early diabetic nephropathy.
3. macroangiopathy, hypertension, coronary heart disease, lower limb vascular disease.
Possess with the next item up and get final product.
(4) diabetic complications mid-term (IV phase)
Complication increases the weight of functional compensation:
1. typical peripheral neuropathy clinical manifestation, tendon reflex weakens or disappear.
2. proliferative diabetic retinopathy.
3. diabetic nephropathy renal failure serum creatinine＞442.5umol/L (5mg/dl).
(5) diabetic complications is heavily endangered the phase (V phase)
Be in a bad way or organ injury or limbs maimed person:
1. diabetic ketoacidotic coma.
2. diabetic hyperosmolar coma.
3. diabetic lactoacidosis is gone into a coma.
4. diabetes merge the severe infections septicemia.
5. diabetic retinopathy is blind.
6. diabetic acromelic gangrene.
7. diabetic osteonecrosis or fracture.
8. diabetic cardiopathy acute myocardial infarction, serious cardiac arrhythmia, heart failure.
9. the diabetic nephropathy uremia that declines.
10. acute cerebrovascular disease.
Possess with the next item up and get final product.
Attached 3, diabetes typing: with reference to " practical internal medicine " by its severity extent be divided into gently, in, weigh three types:
1. light-duty: fasting glucose＜8.3mmol/L (150mg/dl).
2. medium-sized: fasting glucose is at 8.3～13.8mmol/L (between 150～250mg/dl).
4. heavy: fasting glucose＞13.8mmol/L (250mg/dl).
(2) test case standard
1, includes the case standard in
(1) meets diagnostic criteria of traditional Chinese medical science diabetes and the dialectical genus intense heat due to deficiency of YIN type syndrome of blood stasis due to qi deficiency person that holds concurrently.
(2) meet doctor trained in Western medicine diabetes diagnosis standard, and possess following condition person simultaneously.
1. divide generic non-insulin-depending type (NIDDM, II type) person.
2. the weight typing belong to light, in, weight person.
3. belong to the diabetic symptom phase (II phase), early stage (III phase) person of diabetic complications by stages.
2, get rid of the case standard: (comprising inadaptation or rejecting standard)
(1) complication such as severe cardiac, brain, liver, kidney is arranged, or merge other serious primary disease, the psychotic;
(2) in nearly 1 month diabetes ketosis, ketoacidosis and the infected are arranged;
(3) noncooperationist refers to cooperate diet control or medication and the person of affecting the treatment in accordance with regulations;
(4) age is under-18s or over-65s patient, or gestation, nursing women, and to this medicine allergy sufferers;
(5) blood glucose height before the medication, but can control through diet, physical exercise therapy etc. have made fasting glucose＜7.8mmol/L, or 2 hours after the meal blood glucose＜11.1mmol/L (200mg/dl) persons;
(6) therapy discontinued less than the regulation course of treatment can't be judged the infull person of curative effect or data.
Two, clinical trial method:
(1) observe case load: this research has 420 routine patients, and wherein 300 people are organized in treatment, matched group 120 people, and inpatient's 305 examples, outpatient's 115 examples, the case source is as shown in table 1:
Table 1 case source (example)
| Unit | Amount to | The treatment group | Matched group |
| The hospital of traditional Chinese hospital, academy of traditional Chinese medicine Changchun, Jilin Renmin Hospital of attached institute of Shandong Traditional Chinese Medicine University Jilin Province | 110 110 100 100 | 80 80 70 70 | 30 30 30 30 |
(2) determining of observational technique and matched group:
This research adopts the perspective method of single blind trial at random to observe, to meeting Chinese and western medicine diagnostic criteria and Chinese medical discrimination standard, and adopt the grouping of simple randomization method through receiving the case of people, exclusion standard screening, entire test adopts single blind method, and the ratio of treatment group and matched group is not more than 3: 1.The random packet of case is by Hospital Attached to Shandong Chinese Medical Univ.'s clinical pharmacology base control, concrete randomization group technology is by the establishment of the random by key (INV, RNA) on Casio computer random assortment card by Hospital Attached to Shandong Chinese Medical Univ.'s clinical pharmacology base research worker, give each clinical hospital after the numbering sealing, the sequencing that the clinical research personnel study by qualified experimenter, number according to envelope, the Kaifeng card taking, the grouping of stipulating by card carries into execution a plan.
Treatment group case load needs greater than 300 examples, and matched group needs to carry out synchronously in four tame hospitals greater than 100 examples, requires the inpatient to account for 2/3, and the outpatient then should strictly control variable factor, and must not surpass 1/3 of total case load.
Curative is pacified (by the medicine of the present invention of Tonghua, Jilin Bai Shan pharmaceutical factory production) I number in the process of the test for quenching one's thirst, the YUQUAN WAN (lot number: 950122) pacify II number for quenching one's thirst that the contrast medicine adopts ChengDu Chinese Medicine Factory to produce.
(3) Therapeutic Method
1, treatment group: taking quenches one's thirst pacifies I number, and 0.4 gram/grain is 3/time, 3 times/day, oral.
2, matched group: taking quenches one's thirst pacifies II number, 9g/ time, 4 times/day, oral.
3, observe certainly from, require the patient to adhere to diet control for a long time, by different labor intensity and build roughly staple food stipulate as follows: body weight staple food every day of having a rest or be above standard is controlled at 250～300g; The labor in general person, every day 300～350g, heavy worker 400～500g every day.Institute's calorific requirement takes the circumstances into consideration to be replenished by non-staple foodstuff beyond the staple food.
4, inactive 2 week of any hypoglycemic medicine above (can take 2 all placebo after the drug withdrawal) is used this medicine then, and heavy diabetics should select morbidity people just.
5, therapeutic process: treatment group and matched group 2 months were 1 course of treatment with medication all, treated and finished, and promptly finished clinical observation.
(4) observation index
1, safety observation:
(1) general physical examination (comprising height, growth, nutrition, blood pressure etc.).
(2) blood, urine, stool routine examination chemical examination.
(3) heart (electrocardiogram), liver (GPT), kidney (BUN) functional check.
2, health giving quality observation
(1) detailed medical history-taking, understanding patient's diet situation, activity, mental status, Diabetes Mellitus Knowledge, stress state etc. influence the factor of change of blood sugar, observe main clinic symptoms and sign, situation of change.
Attached: the scoring method of tcm syndrome
The card shape ++++++
Thirsty polydipsia dry mouth and throat is difficult to dry mouth and tougue, the time xerocheilia,
Stand, daily drink 3 tending to drink water, day drink tending to drink water,
Above water 2～3 thermos flasks of thermos flask
(6000ml) (4000～6000ml)
The polyorexia honey stomach, it is strong often to feel appetite, and hungry appetite is stronger,
Hunger, the sense of solar eclipse staple food is obvious, and hunger sensation is arranged during solar eclipse
1.5 the above staple food of jin is (500g is following) more than 1 jin
750g (below the 750g～
More than the 500g)
The dysphoria with feverish sensation in the chest palms and soles brothers like cold, vexed feverish sensation in the palms and soles, the Chang Wuhou brothers heart
It is vexed rather not feel vexed thermocouple sense
Constipation abdominal distention, dry stool are tied every dry stool and are difficult to resolve, and every dry stool is difficult to resolve
Once＜2～3 a day septum secundum 1 day was once on 3rd～6
The fatigue and weakness tetraparesis is unable, limbs fatigue, and exerting oneself has tired sense,
Can not finishing daily worker, to adhere to that by force daily worker can finish daily
Do work
Spontaneous perspiration is sweating constantly, moving then motionless be the movable back sweating of skin tide
Increase the weight of to wet moving slightly then antiperspirant skin wet
Many
Face color of the lip dark face color is dark and gloomy unglazed, and dark simple and unadorned the lip of face color of the lip is dark red,
The lip color is purple but glossy
The numb limbs and tense tendons numb pain is more outstanding, has idol that slight fiber crops are arranged during numb pain
Or the lasting existence of pain, be difficult to take place, can bear wood or pain
Stand and be subjected to
Feeling of oppression and pain in the chest often outbreak under rest state often, the labor idol has slight painful
Take place, outbreak is tired promptly outstanding repeatedly, and idol needs pain, does not take medicine
Toss about and feel uneasy, but need the spontaneous remission of clothes medication treatment
Medicine could be alleviated
Picture of the tongue, pulse condition get final product with text description.
(2) on an empty stomach and 2 hours after the meal blood sugar test, after the medication whenever biweekly.
(3) twenty-four-hour urine sugar detection by quantitative, after the medication whenever biweekly.
(4) lipid determination.
(5) glycosylated hemoglobin is measured.
(6) Determination of Blood Rheology.
Five, efficacy assessment standard
(1) curative effect determinate standard
Change as criterion (is standard with Ministry of Public Health new Chinese medicine clinical research in 1993 guideline) according to clinical symptoms and laboratory examination.
1, produce effects: treatment back symptom disappears substantially, fasting glucose＜7.2mmol/L (130mg/dl), and 2 hours after the meal blood glucose＜8.3mmol/L (150mg/dl), twenty-four-hour urine sugar is gram quantitatively＜10.0; Or blood glucose, twenty-four-hour urine sugar quantitatively descends more than 30% before the treatment.
2, effective: treatment back symptom is obviously improved, fasting glucose＜8.3mmol/L (150mg/dl), and 2 hours after the meal blood glucose＜10mmol/L (180mg/dl), twenty-four-hour urine sugar is gram quantitatively＜25.0; Or blood glucose, twenty-four-hour urine sugar quantitatively descends 10～29% before the treatment.
3, invalid: treatment back symptom does not have obvious improvement, and blood glucose, glucose in urine descend and do not reach above-mentioned standard.
(2) tcm syndrome criterion of therapeutical effect
1, produce effects: treatment back symptom integral value descends＞2/3.
2, effective: treatment back symptom integral value descends between 2/3～1/3.
3, invalid: treatment back symptom integral value descends not as good as 1/3.
Annotate: (1) single symptom statistics also can adopt this method to judge curative effect.
(2) primary symptom ++++++-score value is respectively 6420
Inferior disease ++++++-score value is respectively 3210
Six, clinical summary and statistical disposition
All data gather, and always import the IBM/PC computer, set up the data base, carry out statistical disposition with POMS (medical statistical procedure), PEMS (the medical statistical procedure of Huaxi Medical Univ).
Statistical processing methods: enumeration data X
2Check, ranked data are analyzed with Ridit, and measurement data is checked with t.
Physical data
One, experimental condition and sex
420 routine patients come from the outpatient service and the inpatient in four tame hospitals (attached institute of Shandong Traditional Chinese Medicine University, Jilin Renmin Hospital, the Jilin Province academy of traditional Chinese medicine, the hospital of traditional Chinese hospital, Changchun), and patient's formation situation sees Table 2.
Table 2 experimental condition and sex composition (example)
| Grouping | Add up to | Experimental condition | Sex | |||
| Be in hospital | Outpatient service | The man | The woman | |||
| Treatment group matched group | 300 120 | 217 87 | 82 33 | 157 67 | 143 53 | |
| Between group | X 2 P | 0.012 ＞0.05 | 0.4219 ＞0.05 | |||
Two groups experimental condition and sex ratio, P＞0.05, difference nonsignificance.
Two, the age
Table 3 age distribution situation (example)
| Grouping | Add up to | 18- | 30- | 40- | 50- | 60-65 | Minimal ages | The maximum age | Mean age |
| Treatment group matched group | 300 120 | 4 1 | 28 14 | 70 27 | 110 34 | 88 44 | 28 years old 29 years old | 65 years old 65 years old | 52.34 ± 9.53 years old 52.41 ± 9.86 years old |
Annotate: age distribution is analyzed through Ridit, μ=0.5916, and P＞0.05, the mean age is checked through t, t=0.0673, P＞0.05.Two groups of patients' age distribution is compared, P＞0.05, difference nonsignificance.
Three, the course of disease:
Table 4 course of disease distribution situation (example)
| Grouping | Add up to | ＜half a year | Half a year- | 1 year- | 5 years- | 10 years- | The shortest course of disease | The longest course of disease | Average course of disease |
| Treatment group matched group | 300 120 | 14 7 | 10 10 | 153 54 | 78 32 | 45 17 | 1 all two weeks | 22 years 20 years | 4.71 ± 4.03 gave birth to 4.87 ± 4.74 years |
Annotate: the course of disease distributes and analyzes through Ridit, μ=0.5822, and P＞0.05, average course of disease is checked through t, t=0.3490, P＞0.05.Two groups of patients' the course of disease distributes relatively, P＞0.05, difference nonsignificance.
Four, the state of an illness
Table 5 state of an illness distribution situation (example)
| Grouping | Add up to | Classification | By stages | |||
| Gently | In | Heavy | The symptom phase | Complication is early stage | ||
| Treatment group matched group | 300 120 | 42 13 | 170 71 | 88 36 | 190 82 | 110 38 |
Annotate: state of an illness classification is analyzed through Ridit, μ=0.4508, P＞0.05;
The state of an illness is by stages through X
2Analyze X
2=0.939, P＞0.05.The classification of two groups of state of an illness, relatively equal P＞0.05 of situation by stages, the difference nonsignificance.
Five, tcm syndrome distributes
Table 6-1 tcm syndrome distribution situation (example)
| Project | Treatment group (n=300) | Matched group (n=120) | Between group | |||||||
| - | + | ++ | +++ | - | + | ++ | +++ | μ | p | |
| The dysphoria in chestpalms-soles constipation lassitude hypodynamia of thirsty many drink polyorexias spontaneous perspiration dim complexion is vexed pain extremity numbness in the heart | 11 43 50 91 9 100 148 130 134 | 36 55 63 94 39 96 83 62 36 | 100 118 124 90 121 84 51 72 73 | 153 84 63 25 131 20 18 36 57 | 0 11 28 37 12 50 66 62 57 | 10 24 23 48 24 37 23 25 18 | 54 57 50 26 35 27 24 28 22 | 56 28 19 9 49 6 7 5 23 | 0.387 0.441 1.402 1.002 1.759 1.655 0.503 1.916 0.586 | ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＞0.05 |
By table 6-1 as can be seen, the every symptom of the traditional Chinese medical science is relatively analyzed through Ridit before two groups of patient, and the P value increases in 0.05, the difference nonsignificance.
Table 6-2 tongue arteries and veins distribution situation (example)
| Red tongue or dark red (ecchymosis) yellow fur | Wiry and frequent pulse or count accurately | ||||
| Have | Do not have | Have | Do not have | ||
| Treatment group matched group | 250 100 | 50 20 | 159 51 | 141 69 | |
| Between group | X2 P | 0 ＞0.05 | 3.78 ＞0.05 | ||
From table 6-2 as can be seen, two groups of preceding tongue arteries and veins situations of patient compare P＞0.05, difference nonsignificance.
Six, carbohydrate metabolism situation
Carbohydrate metabolism situation X ± SD before table 7 treatment
| The example number | Fasting glucose mmol/L | The example number | 2h blood glucose mmol/L after the meal | The example number | The quantitative g of 24h glucose in urine | The example number | Glycosylated hemoglobin % | ||
| Treatment group matched group | 300 120 | 12.22±3.21 12.66±3.46 | 300 120 | 16.61±4.22 17.40±4.44 | 300 120 | 22.71±13.32 22.15±10.72 | 79 30 | 2.70±1.00 2.92±0.62 | |
| Between group | t p | 1.2408 ＞0.05 | 1.7074 ＞0.05 | 0.4543 ＞0.05 | 1.3785 ＞0.05 | ||||
Fasting glucose before two groups of patient, 2 hours after the meal blood glucose, twenty-four-hour urine sugar quantitatively reaches glycosylated hemoglobin relatively, P＞0.05, the equal nonsignificance of difference.
Seven, blood fat
Hypercholesterolemia, high triglyceride reach before table 8 treatment
The high density lipoprotein abnormal conditions are analyzed (mmol/L)
| The example number | Cholesterol | The example number | Triglyceride | The example number | High density lipoprotein | ||
| Treatment group matched group | 85 31 | 6.92±1.24 6.65±0.72 | 184 66 | 1.90±0.55 1.93±0.54 | 76 35 | 0.82±0.15 0.81±0.18 | |
| Group | t | 1.4471 | 0.3820 | 0.3060 | |||
| Between | p | ＞0.05 | ＞0.05 | ＞0.05 |
Before two groups of patient high serum total cholesterol, high serum triglycerides, serum high-density LP anomaly ratio, P＞0.05, the equal nonsignificance of difference.
Comprehensive above-mentioned every, between treatment group and the matched group, the equal nonsignificance of the difference of physical data, better harmonious between group, have comparability.
The result
One, total effects
Table 9 total effects analysis (routine %)
| Grouping | Produce effects example % | Effective routine % | Invalid routine % | Total effective rate % | R |
| Treatment group (n=300) matched group (n=120) | 74(24.67) 15(12.50) | 188(62.67) 64(53.33) | 38(12.66) 41(34.17) | 87.33 65.83 | 0.4617 0.5958 |
Ridit analyzes: μ=4.301, P＞0.01.
Two groups of total effectses compare, P＞0.01, and treatment group curative effect obviously is better than matched group.
Two, tcm syndrome curative effect:
Table 10-1 tcm syndrome efficacy analysis (routine %)
| Grouping | Produce effects example % | Effective routine % | Invalid routine % | Total effective rate % | R |
| Treatment group (n=300) matched group (n=120) | 196(65.33) 50(41.67) | 86(28.67) 48(40.00) | 18(6.0) 22(18.33) | 94.00 81.60 | 0.4621 0.5947 |
Ridit analyzes: μ=4.253, P＞0.01.
Two groups of tcm syndrome curative effects compare, P＞0.01, and the curative effect of treatment group tcm syndrome obviously is better than matched group.
The table every symptoms and therapeutic effect of the 10-2 traditional Chinese medical science (example)
| Syndrome | Group | Before the treatment | After the treatment | In the group | Between group | ||||||||
| - | + | ++ | +++ | - | + | ++ | +++ | R | P | R | P | ||
| The dysphoria in chestpalms-soles constipation lassitude hypodynamia of thirsty many drink polyorexias spontaneous perspiration dim complexion is vexed pain extremity numbness in the heart | Treatment group treatment of control group group treatment of control group group treatment of control group group treatment of control group group treatment of control group group treatment of control group group treatment of control group group treatment of control group group control group | 11 0 43 11 50 28 91 37 9 12 100 50 148 66 130 62 134 57 | 36 10 55 24 63 23 94 48 39 24 96 37 83 23 62 25 36 18 | 100 54 118 57 124 50 90 26 121 35 84 27 51 24 72 28 73 22 | 153 56 84 28 63 19 25 9 131 49 20 6 18 7 36 5 57 23 | 152 31 201 63 193 71 249 82 116 30 233 94 223 84 229 76 215 72 | 125 62 87 43 88 37 46 31 153 53 61 21 64 28 58 36 69 29 | 20 25 9 14 16 12 3 6 28 34 6 5 13 8 12 8 16 19 | 3 2 3 0 3 0 2 1 3 3 0 0 0 0 1 0 0 0 | 368.73 129.47 278.49 95.97 226.15 64.23 190.84 39.58 339.59 59.34 148.52 29.38 58.18 7.303 103.40 14.38 122.68 27.54 | ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 | 4.83 2.62 0.97 2.42 4.00 0.026 0.76 2.08 2.25 | ＜0.01 ＜0.01 ＞0.05 ＜0.05 ＜0.01 ＞0.05 ＞0.05 ＜0.05 ＜0.05 |
Table 10-2: medicine of the present invention and YUQUAN WAN all improve significantly to every cardinal symptom of diabetes (type ii diabetes) patient, and medicine of the present invention to thirsty polydipsia, polyorexia, fatigue and weakness, the improvement effect of vexed pain, numb limbs and tense tendons, constipation symptom obviously is better than YUQUAN WAN in the heart, and the improvement effect and the YUQUAN WAN of symptoms such as dysphoria with feverish sensation in the chest palms and soles, spontaneous perspiration, dim complexion are not had significant difference.
Table 10-3 tongue arteries and veins situation of change
| Before the treatment | After the treatment | |||||||
| Red tongue dark red (ecchymosis) yellow fur | Thready and rapid pulse or stringy and rapid pulse | Red tongue dark red (ecchymosis) yellow fur | Thready and rapid pulse or stringy and rapid pulse | |||||
| Have | Do not have | Have | Do not have | Have | Do not have | Have | Do not have | |
| Treatment group (n=300) 250 matched groups (n=120) 100 | 50 20 | 159 49 | 141 71 | 114 64 | 186 56 | 60 32 | 240 88 | |
| Between group | X2 0 3.78 8.2526 2.2269 P ＞0.05 ＞0.05 ＜0.01 ＜0.01 | |||||||
The tongue arteries and veins compares after two groups of patient, P＜0.01, and prompting treatment group is better than matched group to the improvement effect of pathologic tongue arteries and veins.
Three, metabolism of blood glucose
The analysis of table 11-1 metabolism of blood glucose (X ± SD)
| Smelting treatment group | Matched group | |||||
| Before the treatment | After the treatment | Difference | Before the treatment | After the treatment | Difference | |
| Fasting glucose (mmol/L) is 2h blood glucose (mmol/L) 24h glucose in urine quantitative (g) after the meal | 12.22±3.21 16.61±4.22 22.77±13.32 | 8.93±2.96 12.15±3.90 14.14±9.38 | ※※3.29±2.61 ※※4.46±3.40 ※※8.63±10.61 | 12.66±3.46 17.40±4.44 22.15±10.72 | 10.22±3.74 14.10±5.16 16.19±9.5 | ※※2.44±2.18△△ ※※3.29±3.03△△ 4※※5.96±6.61△ |
Annotate: self compares before and after the treatment: ※ ※ P＜0.01;
The two groups of differences in treatment back compare: △ △ P＜0.01; △ P＜0.05.
Table 11-1 shows: two groups all can obviously reduce patient's fasting glucose, 2h blood glucose and 24h glucose in urine are quantitative after the meal; And the effect of treatment group obviously is better than matched group.
Table 11-2 fasting glucose situation of change table (example)
| Produce effects | Effectively | Invalid | Total effective rate | |
| Treatment group (n=300) matched group (n=120) | 115(38.33％) 21(17.5％) | 147(49％) 58(48.33％) | 38(12.67％) 41(34.17％) | 87.33％ 65.83％ |
Ridit analyzes, μ=5.044, and P＜0.01, the difference significance, the curative effect that prompting treatment group reduces fasting glucose obviously is better than matched group.
Table 11-3 is 2h change of blood sugar information slip after the meal
| Produce effects | Effectively | Invalid | Total effective rate | |
| Treatment group (n=300) matched group (n=120) | 107(35.67％) 14(11.67％) | 152(50.67％) 64(53.33％) | 41(13.66％) 42(35.00％) | 86.33％ 65.00％ |
Ridit analyzes, μ=5.523, and P＜0.01, the difference significance, the prompting treatment group reduction curative effect of 2 hours blood glucose after the meal obviously is better than matched group.
Four, the influence of glycosylated hemoglobin:
Table 12 glycosylated hemoglobin (X ± SD)
| Before the treatment | After the treatment | Difference | The group internal ratio | Difference ratio between group | |||
| t | p | t | p | ||||
| Treatment group (n=79)＜0.05 matched group (n=30) | 270±1.00 292±0.62 | 2.20±0.52 2.88±0.62 | 0.5094±0.8543 0.0433±0.1010 | 5.30 2.35 | ＜0.00 ＜0.01 | 1.99 | |
Table 12 explanation: medicine of the present invention and YUQUAN WAN all can obviously reduce patient's glycosylated hemoglobin (P＜0.01, P＜0.05), and the effect of medicine of the present invention is better than YUQUAN WAN (difference ratio between group: P＜0.05).
Five, Blood Lipid
(1) blood fat Change in Mean:
The comparison of blood fat average before and after the table 13-1 treatment (mmol/L, X ± SD)
| Unusual routine number | Before the treatment | After the treatment | Difference | ||
| The different fat of the sweet blood oil disease close whiteness of three high eggs of the solid high ester of disease of high pure courage blood is normal | Treatment group treatment of control group group treatment of control group group control group | 85 31 184 66 76 35 | 6.92±1.24 6.65±0.72 1.90±0.55 1.93±0.54 0.82±0.15 0.81±0.18 | 6.11±1.22** 6.38±0.78** 1.66±0.48** 1.76±0.61* 1.00±0.32** 0.83±0.17▲ | 6.92±1.24 0.27±0.51△ 0.24±0.12 0.17±0.18△ -0.18±0.28 -0.02±0.08△△ |
Annotate: compare before and after the treatment: * P＜0.05, * * P＜0.01;
▲P＞0.05。
By table 13-1 as can be seen, medicine of the present invention unusually all improves significantly to diabetes (type ii diabetes) patient's cholesterol, triglyceride and high density lipoprotein, and YUQUAN WAN is only to serum total cholesterol and the triglyceride effect of having clear improvement.Difference is relatively pointed out: the effect of drug metabolism disorder of the present invention is better than YUQUAN WAN.
Two groups of blood fat reducing curative effects of table 13-2 are (example) relatively
| n | Effective routine % | Invalid routine % | Total effective rate | X 2 | P |
| Solid＜0.05 pure glycerine of the courage＜close egg of the high fat of 0.05 three ester＜0.05 degree is white | Treatment group treatment of control group group treatment of control group group control group | 85 31 184 66 76 35 | 43 9 74 16 43 12 | 42 22 110 50 33 23 | 50.59％ 29.03％ 40.22％ 24.24％ 56.58％ 34.29％ | 4.27 5.38 4.76 |
Table 13-2 explanation, the effect that the peace of quenching one's thirst is regulated patient's disorders of lipid metabolism obviously is better than YUQUAN WAN (P＜0.05).
Seven, hemorheology:
Table 14 treatment group hemorheology situation of change (X ± SD)
| Before the treatment | After the treatment | Difference | |
| Whole blood is cut annual whole blood than height and is cut annual plasma viscosity packed cell volume Fibrinogen than hanging down | 7.00±1.60 9.54±2.47 1.70±0.10 46.00±4.93 4.19±1.03 | 6.55±1.16** 9.02±2.13* 1.72±0.09** 45.62±4.40▲ 3.93±0.92** | 0.44±1.07 0.52±1.55 0.04±0.10 0.39±2.98 0.26±1.07 |
Annotate: relatively preceding with treatment: * shows P＜0.05, and * * shows P＜0.01; ▲ P＞0.05
Table 14 explanation: medicine of the present invention is cut viscosity, whole blood to diabetes (type ii diabetes) patient whole blood than height and is cut indexs such as viscosity, plasma viscosity, Fibrinogen and have significant improvement effect than low, and not obvious to the influence of packed cell volume.
The discrimination method of medicine of the present invention is as follows:
(1) gets this product content 4g, add 65% ethanol 50ml, supersound process 30 minutes, filter, filtrate is put and is concentrated into 5ml in the water-bath, adds water 15ml, extract with n-butyl alcohol 30ml jolting, get the n-butyl alcohol evaporate to dryness, residue adds vitriolic 45% alcoholic solution (7 → 100) 15ml, reflux 1 hour is flung to ethanol, and residue adds chloroform 10ml jolting and extracts, divide and get chloroform layer, use an amount of anhydrous sodium sulfate dehydration, filter, filtrate is concentrated into 1ml, as need testing solution.Other gets panoxadiol, panaxatriol's reference substance, adds dehydrated alcohol and makes the mixed solution that every 1ml contains 1mg, as the Radix Ginseng reference substance solution.Get the Sarsasapogenin reference substance again, add benzene and make the solution that every 1ml contains 5mg, as Rhizoma Anemarrhenae reference substance solution.Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 5 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, with cyclohexane extraction-acetone (2: 1) is developing solvent, launches, and takes out, dry, spray is with sulphuric acid methanol solution (1 → 2), at 105 ℃ of baking approximate numbers minute, inspects under the daylight.For looking in the product chromatograph, with the corresponding position of reference substance chromatograph on, the speckle of apparent same color respectively.
(2) it is tolerant to get this product 20 intragranulars, adds water 50ml, and supersound process 30 minutes is centrifugal, centrifugal liquid adds dilute hydrochloric acid solution and transfers pH to 2.0, and usefulness ethyl acetate extraction secondary (30,20ml), merge ethyl acetate liquid, evaporate to dryness, residue add methanol 1ml makes dissolving, as need testing solution.Other gets Radix Salviae Miltiorrhizae control medicinal material 3.0g, shines medical material solution in pairs with legal system.Get the protocatechualdehyde reference substance again, add methanol and make the solution that every 1ml contains 1mg, in contrast product solution.Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), drawing each 5 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, is developing solvent with benzene-ethyl acetate-formic acid (8: 5: 0.8), launch, take out, dry, spray is with 1% phloroglucinol ethanol-concentrated sulphuric acid (1: 1) liquid, under daylight, inspect, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Content of medicines assay method of the present invention is as follows:
Precision takes by weighing this product 1.6g, put in the filter paper of apparatus,Soxhlet's, it is an amount of to add 1% methanol hydrochloride solution, soaks 1 hour, and putting refluxes in the water-bath is extracted into extracting liquid colourless, extracting solution is moved in the 50ml measuring bottle, with a small amount of 1% methanol hydrochloride solution washing container, washing liquid is incorporated in the extracting solution, adds 1% methanol hydrochloride solution and is diluted to scale, shake up, as need testing solution.Other gets the berberine hydrochloride reference substance, adds 1% methanol hydrochloride solution, makes the solution that every 1ml contains 0.2mg, in contrast product solution.Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 1 μ l of above-mentioned two kinds of solution, put respectively in same be on the silica gel g thin-layer plate of binding agent with the sodium carboxymethyl cellulose, (4: 1: 1: lower floor's solution 1) was developing solvent with ethyl acetate-chloroform-methanol-ammonia, put with in ammonia steam and 15 minutes the chromatography cylinder of developing solvent presaturation simultaneously, launch, take out, dry, carry out the fluorescence linear scanning according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B thin layer chromatography scanning), excitation wavelength is 313nm, measures test sample and reference substance fluorescence intensity integrated value, calculate, promptly.Every of this product contains Rhizoma Coptidis with berberine hydrochloride (C
20H
18ClNO
4) meter, must not be less than 2.5mg.
Claims (10)
1. a treatment Chinese medicine composition is characterized in that it is made up of effective ingredient and/or pharmaceutically acceptable excipient, wherein prepares the Chinese crude drug that described raw materials of effective components comprises following weight portion consumption:
Radix Rehmanniae 4-8 Rhizoma Anemarrhenae 3-7
Rhizoma Coptidis 1-4 Cortex Lycii 2-6
Fructus Lycii 1-4 Rhizoma Polygonati Odorati 2-5
Radix Ginseng 1-4 Radix Salviae Miltiorrhizae 2-5.
2. Chinese medicine composition according to claim 1 is characterized in that the consumption of raw material of Chinese medicine is: Radix Rehmanniae 5-7 Rhizoma Anemarrhenae 4-6
Rhizoma Coptidis 1-3 Cortex Lycii 3-5
Fructus Lycii 1-3 Rhizoma Polygonati Odorati 2-4
Radix Ginseng 1-3 Radix Salviae Miltiorrhizae 2-4.
3. Chinese medicine composition according to claim 1 is characterized in that the consumption of raw material of Chinese medicine is:
Radix Rehmanniae 6 Rhizoma Anemarrhenaes 5
Rhizoma Coptidis 2 Cortex Lycii 4
Fructus Lycii 2 Rhizoma Polygonati Odorati 3
Radix Ginseng 2 Radix Salviae Miltiorrhizaes 3.
4. according to claim 1,2 or 3 described Chinese medicine compositions, it is characterized in that the raw material of Chinese medicine Radix Ginseng can use Radix Ginseng, Radix Ginseng Rubra or its extract to replace.
5. the preparation method of any one described Chinese medicine composition among the claim 1-4, it comprises and takes by weighing above-mentioned consumption, directly with raw material of Chinese medicine dry levigation respectively, mixing.
6. the preparation method of any one described Chinese medicine composition among the claim 1-4, it comprises Radix Ginseng and partly measures Rhizoma Anemarrhenae powder and is broken into fine powder, sieves; Rhizoma Coptidis powder is broken into coarse powder, adds an amount of decoction of water 3 times, and each 1.5 hours, gradation filtered, merging filtrate; The Rhizoma Anemarrhenae extracting in water of all the other five tastes and half amount three times, each 1.5 hours, merging filtrate merged filtrate and Rhizoma Coptidis filtrate, was concentrated into 60 ℃ of survey relative densities and is 1.18 thick paste; Add Radix Ginseng and partly measure Rhizoma Anemarrhenae fine powder, mixing, drying is ground into fine powder.
7. the preparation method of Chinese medicine composition according to claim 6 is characterized in that it being that adding starch is an amount of, and mixing sieves, and packing is made 1000, promptly.
8. according to the preparation method of claim 5,6 or 7 described Chinese medicine compositions, it is characterized in that the raw material of Chinese medicine Radix Ginseng can use Radix Ginseng, Radix Ginseng Rubra or its extract to replace.
9. the discrimination method of the described Chinese medicine composition of claim 3, it comprises:
(1) gets this product content 4g, add 65% ethanol 50ml, supersound process 30 minutes, filter, filtrate is put and is concentrated into 5ml in the water-bath, adds water 15ml, extract with n-butyl alcohol 30ml jolting, get the n-butyl alcohol evaporate to dryness, residue adds vitriolic 45% alcoholic solution (7 → 100) 15ml, reflux 1 hour is flung to ethanol, and residue adds chloroform 10ml jolting and extracts, divide and get chloroform layer, use an amount of anhydrous sodium sulfate dehydration, filter, filtrate is concentrated into 1ml, as need testing solution; Other gets panoxadiol, panaxatriol's reference substance, adds dehydrated alcohol and makes the mixed solution that every 1ml contains 1mg, as the Radix Ginseng reference substance solution.Get the Sarsasapogenin reference substance again, add benzene and make the solution that every 1ml contains 5mg, as Rhizoma Anemarrhenae reference substance solution; Thin layer chromatography test according to an appendix VIB of Chinese Pharmacopoeia version in 2000, draw each 5 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, with cyclohexane extraction-acetone of 2: 1 was developing solvent, launched, and took out, dry, spray is with 1: 2 sulphuric acid methanol solution, at 105 ℃ of baking approximate numbers minute, inspects under the daylight; For looking in the product chromatograph, with the corresponding position of reference substance chromatograph on, the speckle of apparent same color respectively.
(2) it is tolerant to get this product 20 intragranulars, adds water 50ml, and supersound process 30 minutes is centrifugal, centrifugal liquid adds dilute hydrochloric acid solution and transfers pH to 2.0, use the ethyl acetate extraction secondary, is respectively 30 and 20ml, merging ethyl acetate liquid at every turn, evaporate to dryness, residue add methanol 1ml makes dissolving, as need testing solution; Other gets Radix Salviae Miltiorrhizae control medicinal material 3.0g, shines medical material solution in pairs with legal system; Get the protocatechualdehyde reference substance again, add methanol and make the solution that every 1ml contains 1mg, in contrast product solution.Thin layer chromatography test according to an appendix VIB of Chinese Pharmacopoeia version in 2000, drawing each 5 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, is developing solvent with benzene-ethyl acetates of 8: 5: 0.8-formic acid, launch, take out, dry, spray 1% phloroglucinol ethanol-concentrated sulfuric acid solution with 1: 1, under daylight, inspect, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
10. the content assaying method of the described Chinese medicine composition of claim 3, it comprises:
Precision takes by weighing this product 1.6g, put in the filter paper of apparatus,Soxhlet's, it is an amount of to add 1% methanol hydrochloride solution, soaks 1 hour, and putting refluxes in the water-bath is extracted into extracting liquid colourless, extracting solution is moved in the 50ml measuring bottle, with a small amount of 1% methanol hydrochloride solution washing container, washing liquid is incorporated in the extracting solution, adds 1% methanol hydrochloride solution and is diluted to scale, shake up, as need testing solution; Other gets the berberine hydrochloride reference substance, adds 1% methanol hydrochloride solution, makes the solution that every 1ml contains 0.2mg, in contrast product solution.According to the described thin layer chromatography test of appendix VIB of Chinese Pharmacopoeia version in 2000, draw each 1 μ l of above-mentioned two kinds of solution, put respectively in same be on the silica gel g thin-layer plate of binding agent with the sodium carboxymethyl cellulose, with 4: 1: 1: lower floor's solution of ethyl acetate-chloroform-methanol of 1-ammonia was developing solvent, put with in ammonia steam and 15 minutes the chromatography cylinder of developing solvent presaturation simultaneously, launch, take out, dry, carry out the fluorescence linear scanning according to an appendix VIB of Chinese Pharmacopoeia version in 2000 thin layer chromatography scanning, excitation wavelength is 313nm, measures test sample and reference substance fluorescence intensity integrated value, calculate, promptly; Every of this product contains Rhizoma Coptidis in berberine hydrochloride, must not be less than 2.5mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100706232A CN100493573C (en) | 2004-07-26 | 2004-07-26 | Chinese traditional medicine composition for lowering blood sugar and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100706232A CN100493573C (en) | 2004-07-26 | 2004-07-26 | Chinese traditional medicine composition for lowering blood sugar and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1726987A true CN1726987A (en) | 2006-02-01 |
| CN100493573C CN100493573C (en) | 2009-06-03 |
Family
ID=35926625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100706232A Expired - Lifetime CN100493573C (en) | 2004-07-26 | 2004-07-26 | Chinese traditional medicine composition for lowering blood sugar and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100493573C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614378A (en) * | 2012-04-26 | 2012-08-01 | 陕西方舟制药有限公司 | Yin nourishing and blood sugar lowering Chinese medicinal composition and preparation method as well as detection method thereof |
| CN102631526A (en) * | 2011-02-14 | 2012-08-15 | 王宇红 | Chinese medicinal composition for treating diabetes mellitus |
| CN106290674A (en) * | 2016-10-12 | 2017-01-04 | 广西河丰药业有限责任公司 | The quality determining method of Corydalis saxicola Bunting injection |
| CN109959749A (en) * | 2017-12-26 | 2019-07-02 | 九芝堂股份有限公司 | A method of radix polygonati officinalis cream is identified using thin-layered chromatography |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103386040A (en) * | 2013-08-09 | 2013-11-13 | 田艺儿 | Hypoglycemic traditional Chinese medicine preparation and preparation method thereof |
-
2004
- 2004-07-26 CN CNB2004100706232A patent/CN100493573C/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631526A (en) * | 2011-02-14 | 2012-08-15 | 王宇红 | Chinese medicinal composition for treating diabetes mellitus |
| CN102631526B (en) * | 2011-02-14 | 2015-07-15 | 王宇红 | Chinese medicinal composition for treating diabetes mellitus |
| CN102614378A (en) * | 2012-04-26 | 2012-08-01 | 陕西方舟制药有限公司 | Yin nourishing and blood sugar lowering Chinese medicinal composition and preparation method as well as detection method thereof |
| CN102614378B (en) * | 2012-04-26 | 2014-01-15 | 陕西方舟制药有限公司 | Yin nourishing and blood sugar lowering Chinese medicinal composition and preparation method as well as detection method thereof |
| CN106290674A (en) * | 2016-10-12 | 2017-01-04 | 广西河丰药业有限责任公司 | The quality determining method of Corydalis saxicola Bunting injection |
| CN109959749A (en) * | 2017-12-26 | 2019-07-02 | 九芝堂股份有限公司 | A method of radix polygonati officinalis cream is identified using thin-layered chromatography |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100493573C (en) | 2009-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100349598C (en) | Medicine for treating high lipemia and its production method | |
| CN1730094A (en) | Ginger and dried orange peel extracts mixture for treating cardiovascular disease | |
| CN1075735C (en) | Compound diabetes-treating Chinese medicine preparation | |
| CN1663597A (en) | Qi-invigorating, blood-nourishing medicinal composition and its preparing method | |
| CN1239183C (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN1726987A (en) | Combined of Chinese traditional medicine for lowering blood sugar, preparation and discrimination method | |
| CN1246011C (en) | Multi-function health care food and application thereof | |
| CN1294936C (en) | Medicine for treating diabetes and its preparation method | |
| CN100335102C (en) | Chinese medicina composition for treating algomenorrhea and its preparation method | |
| CN1733089A (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN1112439A (en) | Chinese medicine for diabetes and its preparation | |
| CN1879706A (en) | 'Shuang Huang Lian' dispersible tablet and preparation method thereof | |
| CN1562337A (en) | Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method | |
| CN1730083A (en) | Yuanhe tablet and process for preparing the same | |
| CN1634496A (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1296080C (en) | Liver clearing blood pressure lowering capsule nd its preparation method | |
| CN1562144A (en) | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method | |
| CN1990022A (en) | Traditional Chinese medicine composition, its preparation and quality controlling means | |
| CN1294925C (en) | Chinese medicine for treating hypertension and hyperlipemia and preparation thereof | |
| CN1726934A (en) | Medication combination of Xuefu Zhuyu in application for preparing hypolipidemic | |
| CN1857554A (en) | Chinese medicine composition for preventing and treating coronary heart disease and its preparing process and quality control method | |
| CN1686273A (en) | Theory and medicine for treating high blood fat, fatty liver, liver fibrosis and preparation method | |
| CN1958025A (en) | Composition of medicine for treating cerebral arteriosclerosis, and preparation method | |
| CN1380081A (en) | Chinese medicine preparation containing curculigo rhizome and epimedium and its preparation method | |
| CN101053626A (en) | Traditional Chinese medicine for treating coronary heart disease and angina pectoris and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: TONGHUA BAISHAN PHARMACEUTICAL Ltd. Assignor: Hua Yuqiang Contract record no.: 2011220000003 Denomination of invention: Chinese traditional medicine composition for lowering blood sugar and its preparation Granted publication date: 20090603 License type: Exclusive License Open date: 20060201 Record date: 20110104 |
|
| ASS | Succession or assignment of patent right |
Owner name: TONGHUA BAISHAN PHARMACEUTICAL LTD Free format text: FORMER OWNER: HUA YUQIANG Effective date: 20140428 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140428 Address after: 134100 Jilin Bay Bay Development Zone, Tonghua County Patentee after: TONGHUA BAISHAN PHARMACEUTICAL Ltd. Address before: 134100 Tonghua province unity Road, Jilin, No. 3333 Patentee before: Hua Yuqiang |
|
| EC01 | Cancellation of recordation of patent licensing contract | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: TONGHUA BAISHAN PHARMACEUTICAL Ltd. Assignor: Hua Yuqiang Contract record no.: 2011220000003 Date of cancellation: 20190813 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20060201 Assignee: TONGHUA HUAXIA PHARMACEUTICAL Co.,Ltd. Assignor: TONGHUA BAISHAN PHARMACEUTICAL Ltd. Contract record no.: X2019990000016 Denomination of invention: Chinese traditional medicine composition for lowering blood sugar and its preparation Granted publication date: 20090603 License type: Exclusive License Record date: 20190815 |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20090603 |